Seurat therapeutics announces novel mechanisms from rat migraine model of intranasal IGF-1
Intranasal insulin-like growth factor-1 (IGF-1) treatment reduces trigeminal pain pathway activation and oxidative stress levels in a rat model of migraine. The therapy has a unique potential to safely prevent migraine headaches through multiple novel mechanisms.